626
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Oxaliplatin immunohybrid nanoparticles in vitro synergistic suppression evaluation in treatment of colorectal cancer

, &
Pages 261-269 | Received 19 Oct 2015, Accepted 21 Jan 2016, Published online: 02 Mar 2016

Figures & data

Figure 1. In vitro cell viability plots of cell control, oxaliplatin, HNP, and immuno-nanoparticles at different time intervals (A) 24 h (B) 48 h (C) 72 h on HT-29 colorectal cancer cell lines.

Figure 1. In vitro cell viability plots of cell control, oxaliplatin, HNP, and immuno-nanoparticles at different time intervals (A) 24 h (B) 48 h (C) 72 h on HT-29 colorectal cancer cell lines.

Figure 2. Morphological nuclear staining by DAPI for nanoparticulate formulations comparable to control and oxaliplatin.

Figure 2. Morphological nuclear staining by DAPI for nanoparticulate formulations comparable to control and oxaliplatin.

Figure 3. Quantitative assessment of apoptotic ratio of cell control, oxaliplatin, OHNPs, and OIHNPs by annexin V-FITC/PI staining at 72 h. Viable cells were conformed with 91.2% of the cells in the LL quadrant.

Figure 3. Quantitative assessment of apoptotic ratio of cell control, oxaliplatin, OHNPs, and OIHNPs by annexin V-FITC/PI staining at 72 h. Viable cells were conformed with 91.2% of the cells in the LL quadrant.

Figure 4. Fluorescent microscopic images of HT-29 colon cancer lines with immunonanoparticles, OHNPs, and pure drug (oxaliplatin) at 24 h and 72 h. Control was visualized by green fluorescence at all time intervals conforming its viability. Oxaliplatin had shown minimal fluorescence of light orange and green representing minimal apoptosis. OIHNPs had shown appreciable apoptosis attributing to the major part of the cells with red fluorescence.

Figure 4. Fluorescent microscopic images of HT-29 colon cancer lines with immunonanoparticles, OHNPs, and pure drug (oxaliplatin) at 24 h and 72 h. Control was visualized by green fluorescence at all time intervals conforming its viability. Oxaliplatin had shown minimal fluorescence of light orange and green representing minimal apoptosis. OIHNPs had shown appreciable apoptosis attributing to the major part of the cells with red fluorescence.

Figure 5. Cell-cycle analysis of HT-29 cells after 72 h of treatment with oxaliplatin, TRAIL, OHNPs, and OIHNPs. Nanoparticles had shown transition S-phase delay with cell-cycle arrest at G2 phase.

Figure 5. Cell-cycle analysis of HT-29 cells after 72 h of treatment with oxaliplatin, TRAIL, OHNPs, and OIHNPs. Nanoparticles had shown transition S-phase delay with cell-cycle arrest at G2 phase.

Figure 6. Caspase-mediated apoptosis induced by oxaliplatin hybrid nanoparticles in comparison with oxaliplatin-treated HT-29 cells confirmed by western blot analysis of pro-apoptotic and antiapoptotic proteins.

Figure 6. Caspase-mediated apoptosis induced by oxaliplatin hybrid nanoparticles in comparison with oxaliplatin-treated HT-29 cells confirmed by western blot analysis of pro-apoptotic and antiapoptotic proteins.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.